This review describes the development of the currently available anti-PD1 Ab-based immunotherapies for advanced melanoma, focusing on their efficacy and immune-related adverse events (irAEs), as well as clinical trials still ongoing for the future treatment of advanced melanoma. The gene discussed is PDCD1; the disease is melanoma.